Bis-indolic compounds as potential new therapeutic alternatives for tularaemia

Frontiers in Cellular and Infection Microbiology

Volumn 5, Issue FEB, 2014, Pages

  Caspar, Yvan ^a,b   Sutera, Vivien ^a,b   Boisset, Sandrine ^a,b   Denis, Jean Noël ^c   Maurin, Max ^a,b  

^a GRENOBLE UNIVERSITY HOSPITAL   (France)

^b UNIV GRENOBLE ALPES   (France)

^c UNIVERSITÉ JOSEPH FOURIER   (France)

Author keywords

Antibacterial activity; Bis indolic compounds; Francisella tularensis; Tularaemia

Indexed keywords

BIS INDOLE DERIVATIVE; DOXYCYCLINE; GENTAMICIN; INDOLE DERIVATIVE; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT;

ANIMAL TISSUE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERICIDAL ACTIVITY; BACTERIOSTASIS; CONTROLLED STUDY; FRANCISELLA TULARENSIS; HARE; HUMAN; HUMAN TISSUE; MINIMUM BACTERICIDAL CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; TULAREMIA; ANTIBACTERIAL ACTIVITY; BIS-INDOLIC COMPOUNDS; CHEMISTRY; DRUG EFFECT; FRANCE; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIAL VIABILITY; MICROBIOLOGY;

ANTIBACTERIAL ACTIVITY; BIS-INDOLIC COMPOUNDS; FRANCISELLA TULARENSIS; TULARAEMIA;

ANTI-BACTERIAL AGENTS; FRANCE; FRANCISELLA TULARENSIS; HUMANS; INDOLES; MICROBIAL SENSITIVITY TESTS; MICROBIAL VIABILITY; TULAREMIA;

EID: 84897923568     PISSN: None     EISSN: 22352988     Source Type: Journal    
DOI: 10.3389/fcimb.2014.00024     Document Type: Article

References (26)

1. Antunes, N. T., Frase, H., Toth, M., and Vakulenko, S. B. (2012). The class A β-Lactamase FTU-1 is native to Francisella tularensis. Antimicrob. Agents Chemother. 56, 666-671. doi: 10.1128/AAC.05305-11.
2. Denis, J.-N., Jolivalt, C., Maurin, M., and Burchak, O. (2013a). Preparation of bis-indole derivatives useful as antibacterials. PCT Int. Appl. WO 2013014104 A1 20130131.
3. Denis, J.-N., Jolivalt, C., Maurin M., and Jeanty, M. (2013b). Preparation of novel bis-indolic derivatives antibacterial drugs and a process for preparing them. PCT Int. Appl. WO 2013014102 A1 20130131.
4. Dennis, D. T., Inglesby, T. V., Henderson, D. A., Bartlett, J. G., Ascher, M. S., Eitzen, E., et al. (2001). Tularemia as a biological weapon: medical and public health management. JAMA 285, 2763-2773. doi: 10.1001/jama.285.21.2763.
5. Dentan, C., Pavese, P., Pelloux, I., Boisset, S., Brion, J.-P., Stahl, J.-P., et al. (2013). Treatment of tularemia in pregnant woman, France. Emerging Infect. Dis. 19, 996-998. doi: 10.3201/eid1906.130138.
6. England, K., am Ende, C., Lu, H., Sullivan, T. J., Marlenee, N. L., Bowen, R. A., et al. (2009). Substituted diphenyl ethers as a broad-spectrum platform for the development of chemotherapeutics for the treatment of tularaemia. J. Antimicrob. Chemother. 64, 1052-1061. doi: 10.1093/jac/dkp307.
7. Gestin, B., Valade, E., Thibault, F., Schneider, D., and Maurin, M. (2010). Phenotypic and Genetic characterization of macrolide resistance in Francisella tularensis subsp. holarctica biovar I. J. Antimicrob. Chemother. 65, 2359-2367. doi: 10.1093/jac/dkq315.
8. Hevener, K. E., Mehboob, S., Su, P.-C., Truong, K., Boci, T., Deng, J., et al. (2012). Discovery of a novel and potent class of F. tularensis enoyl-reductase (FabI) inhibitors by molecular shape and electrostatic matching. J. Med. Chem. 55, 268-279. doi: 10.1021/jm201168g.
9. Johansson, A., Berglund, L., Gothefors, L., Sjöstedt, A., and Tärnvik. A. (2000). Ciprofloxacin for treatment of tularemia in children. Pediatr. Infect. Dis. J. 19, 449-453. doi: 10.1097/00006454-200005000-00011.
10. Johansson, A., Urich, S. K., Chu, M. C., Sjöstedt, A., and Tärnvik, A. (2002). In vitro susceptibility to quinolones of Francisella tularensis subsp. tularensis. Scand. J. Infect. Dis. 34, 327-330. doi: 10.1080/00365540110080773.
11. Kaya, A., Uysal, I. O., Güven, A. S., Engin, A., Gültürk, A., Íçagasioǧlu, F. D., et al. (2011). Treatment failure of gentamicin in pediatric patients with oropharyngeal tularemia. Med. Sci. Monit. 17, 376-380. doi: 10.12659/MSM.881848.
12. Kingry, L. C., Cummings, J. E., Brookman, K. W., Bommineni, G. R., Tonge, P. J., and Slayden, R. A. (2013). The Francisella tularensis FabI enoyl-acyl carrier protein reductase gene is essential to bacterial viability and is expressed during infection. J. Bacteriol. 195, 351-358. doi: 10.1128/JB.01957-12.
13. Kudelina, R. I., and Olsufiev, N. G. (1980). Sensitivity to macrolide antibiotics and lincomycin in Francisella tularensis holarctica. J. Hyg. Epidemiol. Microbiol. Immunol. 24, 84-91.
14. Kumar, K., Awasthi, D., Lee, S.-Y., Cummings, J. E., Knudson, S. E., Slayden, R. A., et al. (2013). Benzimidazole-based antibacterial agents against Francisella tularensis. Bioorg. Med. Chem. 21, 3318-3326. doi: 10.1016/j.bmc.2013.02.059.
15. Larssen, K. W., Afset, J. E., Heier, B. T., Krogh, T., Handeland, K., Vikøren, T., et al. (2011). Outbreak of tularaemia in central norway, January to March 2011. Euro Surveill. 16:pii 19828. Available online at: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19828.
16. Lu, H., England, K., am Ende, C., Truglio, J. J., Luckner, S., Reddy, B. G., et al. (2009). Slow-onset inhibition of the FabI enoyl reductase from Francisella tularensis: residence time and in vivo activity. ACS Chem. Biol. 4, 221-231. doi: 10.1021/cb800306y.
17. Maurin, M., Mersali, N. F., and Raoult, D. (2000). Bactericidal activities of antibiotics against intracellular Francisella tularensis. Antimicrob. Agents Chemother. 44, 3428-3431. doi: 10.1128/AAC.44.12.3428-3431.2000.
18. Maurin, M., Pelloux, I., Brion, J.-P., Del Banõ, J.-N., and Picard, A. (2011). Human tularemia in France, 2006-2010. Clin. Infect. Dis. 53, e133-e141. doi: 10.1093/cid/cir612.
19. Mehboob, S., Hevener, K. E., Truong, K., Boci, T., Santarsiero, B. D., and Johnson, M. E. (2012). Structural and enzymatic analyses reveal the binding mode of a novel series of Francisella tularensis enoyl reductase (FabI) inhibitors. J. Med. Chem. 55, 5933-5941. doi: 10.1021/jm300489v.
20. Pérez-Castrillón, J. L., Bachiller-Luque, P., Martin-Luquero, M., Mena-Martin, F. J., and Herreros, V. (2001). Tularemia epidemic in northwestern Spain: clinical description and therapeutic response. Clin. Infect. Dis. 33, 573-576. doi: 10.1086/322601.
21. Petrosino, J. F., Xiang, Q., Karpathy, S. E., Jiang, H., Yerrapragada, S., Liu, Y., et al. (2006). Chromosome rearrangement and diversification of Francisella tularensis revealed by the type B (OSU18) genome sequence. J. Bacteriol. 188, 6977-6985. doi: 10.1128/JB.00506-06.
22. Rohmer, L., Brittnacher, M., Svensson, K., Buckley, D., Haugen, E., Zhou, Y., et al. (2006). Potential source of Francisella tularensis live vaccine strain attenuation determined by genome comparison. Infect. Immun. 74, 6895-6906. doi: 10.1128/IAI.01006-06.
23. Rotem, S., Bar-Haim, E., Cohen, H., Elia, U., Ber, R., Shafferman, A., et al. (2012). Consequences of delayed ciprofloxacin and doxycycline treatment regimens against Francisella tularensis airway infection. Antimicrob. Agents Chemother. 56, 5406-5408. doi: 10.1128/AAC.01104-12.
24. Rydén, P., Björk, R., Schäfer, M. L., Lundström, J. O., Petersén, B., Lindblom, A., et al. (2012). Outbreaks of tularemia in a boreal forest region depends on mosquito prevalence. J. Infect. Dis. 205, 297-304. doi: 10.1093/infdis/jir732.
25. Sutera, V., Levert, M., Burmeister, W. P., Schneider, D., and Maurin, M. (2014). Evolution toward high-level fluoroquinolone resistance in Francisella species. J. Antimicrob. Chemother. 69, 101-110. doi: 10.1093/jac/dkt321.
26. Tärnvik, A., and Chu, M. C. (2007). New approaches to diagnosis and therapy of tularemia. Ann. N.Y Acad. Sci. 1105, 378-404. doi: 10.1196/annals.1409.017.